Epothilones and the next generation of phase III trials for prostate cancer

BJU International

Volumn 96, Issue 3, 2005, Pages 296-302

  Bhandari, Manish S ^a   Hussain, Maha ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Epothilones; Hormone refractory prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ATRASENTAN; BETA TUBULIN; BEVACIZUMAB; BMS 310705; DIPHENHYDRAMINE; DOCETAXEL; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; IXABEPILONE; MACROGOL; MACROLIDE; MITOXANTRONE; PACLITAXEL; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RANITIDINE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINCA ALKALOID; WARFARIN;

ANTINEOPLASTIC ACTIVITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DEHYDRATION; DEPOLYMERIZATION; DIARRHEA; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; FEBRILE NEUTROPENIA; HEADACHE; HUMAN; META ANALYSIS; MICROTUBULE; NEUROPATHY; NEUTROPENIA; NONHUMAN; PAIN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHINITIS; SACCHAROMYCES CEREVISIAE; SENSORY NEUROPATHY; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; EPOTHILONES; ESTRAMUSTINE; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 23244451398     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05618.x     Document Type: Review

References (54)

1. Jemal A, Murray T, Ward E et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55: 10-30
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555
3. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer, local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20: 3199
4. Carroll PR, Kantoff PW, Balk SP et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002; 60 (Suppl): 1
5. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002; 60: 201
6. Kelly Wm, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 607
7. Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002; 168: 542
8. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol, 1997; 15: 382
9. Petrylak DP, Tangen C, Hussain M et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
10. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
11. Bhandari MS, Petrylak DP, Hussain M. Clinical trials in metastatic prostate cancer - has there been real progress in the past decade? Eur J Cancer 2005; 41: 941-53
12. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325-33
13. Gerth K, Bedorf N, Hofle G et al. Epothilons A and B. Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria): Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49: 560-3
14. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550, a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429-37
15. Goodin S, Kane MP, Rubin EH. Epothilones, mechanism of action and biological activity. J Clin Oncol 2004; 22: 2015-25
16. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13: 134-6
17. Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-6
18. Trielli MO, Andreassen PR, Lacroix FB et al. Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J Cell Biol 1996; 135: 689-700
19. Wahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72-9
20. Belotti D, Vergani V, Drudis T et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843-9
21. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem 1997; 272: 2534-41
22. Nogales E, Wolf SG, Khan IA et al. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 1995; 375: 424-7
23. Bode CJ, Gupta ML Jr, Reiff EA et al. Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002; 41: 3870-4
24. Giannakakou P, Gussio R, Nogales E et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000; 97: 2904-9
25. Verrills NM, Flemming CL, Liu M et al. Microtubule alterations and mutations induced by desoxyepothilone B. Implications for drug-target interactions. Chem Biol 2003; 10: 597-607
26. Wartmann M, Altmann K-H. The biology and medicinal chemistry of epothilones. Curr Med Chem Anti-Canc Agents 2002; 2: 123-48
27. Hussain M, Faulkner J, Vaishampayan U et al. Epithilone B, (Epo-B) analogue BMS-247550a (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111). Program and Abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004. New Orleans, Louisiana. Abstract 4510
28. Kelly WK, Galsky MD, Small EJ et al. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): Updated results. Program and Abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, Louisiana. Abstract 509
29. Rosenberg JE, Galsky MD, Weinberg V et al. Response to second-line taxane-based therapy after first-line epothilone B analogue BMS 247550 (BMS) therapy in hormone refractory prostate cancer. Abstracts of the ASCO Prostate Cancer Symposium; February 17-19, 2005; Orlando, Florida. Abstract 267
30. Vanteenkiste JF, Breton JL, Sandler A et al. A randomized phase II study of epothilone analog BMS-247550 in patients with non-small cell lung cancer who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 626
31. Mekhail T, Chung C, Holden S et al. Phase I trial of novel epothilone B analog BMS-310705 IV q21 days. Proc Am Soc Clin Oncol 2003; 22: 129, A515
32. Sessa C, Perotti A, Malossi A et al. Phase I and pharmacokinetic study of the novel epothilone BMS-310705 in patients with advanced solid cancer. Proc Am Soc Clin Oncol 2003; 22: 130, A519
33. Wartmann M, Koppler J, Larigot M et al. Epothilones A and B accumulate several-hundred fold inside cells. Proc Am Soc Cancer Res 2000; 41: 213, A1362
34. Hussain A, Dipaola RS, Baron AD et al. A, Phase I. trial of weekly EP0906 in patients with hormone-refractory prostate cancer (HRPC). Program and Abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004; New Orleans, Louisiana. Abstract 4563
35. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110-6
36. Nelson JB, Lee WH, Nguyen SH et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997; 57: 35-7
37. Mundy GR, Yin JJ, Mohammad KS et al. A. Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci USA 2003; 100: 10588-9
38. Yin JJ, Mohammad KS, Kakonen SM et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100: 10954-9
39. Nelson JB, Chan-Tack K, Hedican SP et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56: 663-8
40. Papandreou CN, Usmani B, Geng Y et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Med 1998; 4: 50-7
41. Nelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 1995; 1: 944-9
42. Pao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA, Jones P. A. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 2001; 10: 903-10
43. Jeronimo C, Henrique R, Campos PF et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 2003; 56: 52-5
44. Wessale JL, Adler AL, Novosad EI et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin Sci (Lond) 2002; 103 (Suppl. 48): 112S-117S
45. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000; 44: 77-87
46. Fizazi K, Yang J, Peleg S et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003; 9: 2587-97
47. Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679-89
48. Carducci M, Nelson JB, Saad F et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. Proc Am Soc Clin Oncol 2004; 23: 396, A4508
49. Nelson JB. Endothelin receptor antagonists. World J Urol 2005; 23: 19-27
50. Rosano L, Spinella F, Salani D et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003; 63: 2447-53
51. Del Bufalo D, Di Castro V, Biroccio A et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002; 61: 524-32
52. Lara PN Jr, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 2004; 3: 165-73
53. Picus J, Halabi S, Rini BI et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2004; 22: 1578A
54. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-7